Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2022 07:00 ET | Source: Psyence Group Inc.

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

TORONTO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural...
September 07, 2022 11:00 ET | Source: Psyence Group Inc.

Psyence Group Announces Amendment and Closing of Previously Announced Private Placement

TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural...
June 02, 2022 07:00 ET | Source: Psyence Group Inc.

Psyence Group Corporate Update

Highlights: Partnership with CRO Clerkenwell Health to design and deliver Psyence’s UK clinical trial progressing; exclusive licensing agreement with Filament HealthDr. Clive Ward-Able has been...
May 31, 2022 14:50 ET | Source: Psyence Group Inc.

Psyence Taps Another Pharma Exec to Drive its Clinical Program

TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
April 19, 2022 07:00 ET | Source: Psyence Group Inc.

Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products

VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE: PSYG | OTCQB: PSYGF) (“Psyence”), a life science biotechnology company pioneering the use of natural...
February 09, 2022 07:00 ET | Source: Psyence Group Inc.

Psyence Group Announces DTC Eligibility Approval in the U.S.

TORONTO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
February 07, 2022 07:00 ET | Source: Psyence Group Inc.

Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility

TORONTO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
January 21, 2022 10:16 ET | Source: Psyence Group Inc.

Psyence looks to expand capital market opportunities in the UK and Europe

TORONTO, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
December 03, 2021 10:30 ET | Source: Psyence Group Inc.

Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6

TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
December 02, 2021 17:30 ET | Source: Psyence Group Inc.

Psyence Group Announces Private Placement

TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...